Johann de Bono

Johann de Bono, MBChB, MSc, PhD, FRCP is Regius Professor of Cancer Research at The Institute of Cancer Research (ICR) and Honorary Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, where he leads one of the world's most productive prostate cancer drug development programs. Prof. de Bono is widely regarded as the architect of modern castration-resistant prostate cancer therapy, having led or co-led the clinical development of both enzalutamide (MDV3100) and abiraterone acetate — two drugs that fundamentally transformed mCRPC management and have together extended the lives of hundreds of thousands of patients. He initiated the first-in-human studies of enzalutamide beginning in 2007, and led the pivotal phase I/II trial (Lancet 2010) that defined its mechanism of action and established its activity across AR-pathway-driven mCRPC. He was a principal investigator and European lead in the COU-AA-301 trial (NEJM 2011) establishing abiraterone plus prednisone as standard post-chemotherapy mCRPC therapy. More recently, Prof. de Bono led the landmark PROfound trial (NEJM 2020), the first randomized phase III study demonstrating the efficacy of a PARP inhibitor (olaparib) in mCRPC with BRCA1/2 or other HRR gene alterations, leading to FDA approval of olaparib for mCRPC in 2020. His laboratory has made seminal contributions to understanding AR splice variants (AR-V7), mechanisms of abiraterone and enzalutamide resistance, and the use of circulating tumor DNA for real-time genomic profiling of prostate cancer. Prof. de Bono has authored over 650 peer-reviewed publications, holds multiple international awards, and is consistently listed among the world's most cited cancer researchers.